1 **TITLE PAGE**

2

3 **Title: Optimal duration of antibiotic treatment for community-acquired**
 4 **pneumonia in adults: a systematic review and duration-effect meta-analysis**

5

6 **Corresponding author**

7 Dr. Yuki Furukawa, MD.

8 Tokyo Musashino Hospital, 4-11-11, Komone, Itabashi-ku, Tokyo, 173-0037, Japan.

9 Phone: +81- 3-5986-3111

10 E-mail: furukawa.y.psy@gmail.com

11

12 **Authors**

13 Dr. Yuki Furukawa, MD.

14 Department of Psychiatry, Tokyo Musashino Hospital, Tokyo, Japan.

15 Department of Neuropsychiatry, University of Tokyo Hospital, Tokyo, Japan

16 Dr. Yan Luo, MD.

17 Department of Health Promotion and Human Behavior, Kyoto University

18 Graduate School of Medicine

19 Dr. Satoshi Funada, MD.

20 Department of Urology, Kyoto University Graduate School of Medicine, Kyoto

21 city, Kyoto, Japan; Department of Health Promotion and Human Behavior,

22 Kyoto University Graduate School of Medicine / School of Public Health, Kyoto,

23 Japan

24 Dr. Akira Onishi, MD, MPH, PhD.

25 Department of Advanced Medicine for Rheumatic diseases, Graduate School of

26 Medicine, Kyoto University

27 Dr. Edoardo G Ostinelli, MD.

28 Department of Psychiatry, University of Oxford, Oxford, UK; Oxford

29 Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre,

30 Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital,

31 Oxford, UK

32 Ms. Tasnim Hamza, MSc, PhD student.

33 Institute of Social and Preventive Medicine, University of Bern, Bern,

34 Switzerland

35 Prof. Toshi A Furukawa, Prof., MD, PhD.

36 Department of Health Promotion and Human Behavior, Kyoto University
 37 Graduate School of Medicine / School of Public Health, Kyoto, Japan
 38 Dr. Yuki Kataoka MD, MPH, DrPH.
 39 Department of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Kyoto,
 40 Japan; Scientific Research Works Peer Support Group (SRWS-PSG), Osaka,
 41 Japan; Section of Clinical Epidemiology, Department of Community Medicine,
 42 Kyoto University Graduate School of Medicine, Kyoto, Japan; Department of
 43 Healthcare Epidemiology, Kyoto University Graduate School of Medicine /
 44 Public Health, Kyoto, Japan

45

46

47 **Word count <3,000 words**

48 2441 words

49

50 **KEY POINTS (76: 75-100 words)**

51

52 **Question:** What is the optimal treatment duration of antibiotics for community-acquired
53 pneumonia (CAP) in adults.?

54

55 **Findings:** This systematic review and duration-effect meta-analysis of 9 trials with
56 2399 patients found that the shorter treatment duration (3-9 days) was likely to be
57 non-inferior to the standard treatment duration (10 days) for CAP in adults if they
58 achieved clinical stability.

59

60 **Meaning:** Shorter antibiotic treatment duration probably achieves the optimal balance
61 between efficacy and treatment burden for CAP in adults.

62

63 **ABSTRACT (337<350 words)**

64 **Importance:** Community-acquired pneumonia (CAP) is a leading cause of morbidity
65 and mortality globally. The optimal duration of antimicrobial therapy remains unclear
66 and controversial.

67 **Objective:** To find the optimal treatment duration with antibiotics for CAP in adults.

68 **Data Sources:** MEDLINE, Embase and CENTRAL from inception to present (25
69 August, 2021).

70 **Study Selection:** All randomized controlled trials comparing the same antibiotics used
71 at the same daily dosage but for different durations for CAP in adults. We included any
72 antibiotics, administered orally or intravenously. We included both outpatients and
73 inpatients but not those admitted to intensive care unit.

74 **Data Extraction and Synthesis:** Two review authors independently screened and
75 extracted data. We conducted random-effects, one-stage duration-effect meta-analysis
76 with restricted cubic splines. We tested the non-inferiority with the pre-specified
77 non-inferiority margin of 10% examined against 10 days using intention-to-treat dataset.

78 **Main Outcomes and Measures:** The primary outcome was clinical improvement at
79 day 15 (range 7-45 days). Secondary outcomes were all-cause mortality, serious adverse
80 events, and clinical improvement at day 30 (15-60 days). We calculated odds ratios.

81 **Results:** We included 9 trials (2399 patients with a mean [SD] age of 61.2 [22.1]; 39%
82 women). The duration-effect curve was monotonic with longer duration leading to
83 lower probability of improvement, and the lower 95%CI curve was constantly above the
84 prespecified non-inferiority margin throughout the examined duration. Harmful
85 outcome curves indicated no association. The average percentage of clinical
86 improvement rate at day 15 in the 10-day treatment arms was 68%. Using that average,
87 we computed the absolute clinical improvement rates at the following durations: a 3-day
88 treatment 75% (95%CI: 68 to 81%), 5-day treatment 72% (66 to 78%), and 7-day
89 treatment 69% (61 to 76%).

90 **Conclusions and Relevance:** Shorter treatment duration probably achieves the optimal
91 balance between efficacy and treatment burden for treating CAP in adults. However, the
92 small number of included studies and the overall moderate to high risk of bias may
93 compromise the certainty of the results. Further research focusing on the shorter
94 duration range is required.

95

96 **Registration:** PROSPERO (CRD 42021273357).

97

98 **Keywords**

99 Community-acquired pneumonia; antibiotic; treatment duration; dose-response
100 meta-analysis
101
102

103 MAIN TEXT (2441<3000 words)

104

105 INTRODUCTION

106 Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality
107 globally, especially among the elderly.¹ In the United States, it is the second most
108 common cause of hospitalization and the top infectious cause of death.^{2,3} The initial
109 treatment for CAP is empirical, with guidelines recommending starting several
110 antibiotics depending on patients' severity and risk factors for certain pathogens.⁴⁻⁶

111 The optimal duration of antimicrobial therapy remains unclear and
112 controversial. The American and British guidelines recommend a minimum of five days
113 of treatment before therapy discontinuation for patients achieving clinical stability.^{4,5}
114 The European guideline states that the duration of treatment should not exceed 8 days in
115 responding patients.⁶ In clinical practice, however, antibiotics for pneumonia are often
116 prescribed for 10 up to 14 days.^{7,8} This may mean that many patients may be receiving
117 more antibiotics than necessary, with a consequent increase in costs and a higher
118 probability of antimicrobial resistance.⁹ Finding optimal duration of antibiotics can
119 facilitate reducing antimicrobial use efficiently. A pair-wise meta-analysis published in
120 2008 found that short-course therapy was non-inferior to long-course therapy regarding
121 clinical success at end-of-therapy, clinical success at late follow-up, microbiological
122 success, relapses, mortality and adverse events.¹⁰ Since then, at least two trials have
123 been reported,^{11,12} which warrants update of the systematic review and meta-analysis. A
124 major limitation of the method used in the previous pair-wise meta-analysis is the
125 arbitrary categorization of durations when the original studies compared different
126 durations, ranging from three to ten days. This resulted in categorizing a seven-day
127 treatment in one trial to short-course and the same in other two trials to long-course.¹³⁻¹⁵

128 We overcame this limitation by using a novel method called
129 dose-effect meta-analysis.¹⁶ It has been used, for example, to identify optimal dose of
130 antidepressants for major depressive disorder¹⁷ and antipsychotics for schizophrenia¹⁸.
131 Unlike conventional categorization-based meta-analyses¹⁹, dose-effect meta-analysis
132 can reveal more fine-grained optimal dose²⁰. By treating duration as dose, we aimed to
133 apply this method to obtain a more specific optimal treatment duration.

134

135 OBJECTIVE

136 To find the optimal treatment duration of antibiotics for CAP in adults.

137

138 METHODS AND ANALYSIS

139 We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses
140 (PRISMA 2020)²¹. The protocol has been prospectively registered in PROSPERO
141 (CRD 42021273357) and can be found in the appendix (eAppendix 1).

142 143 **Data sources**

144 **Criteria for considering studies for this review**

145 *Types of studies*

146 To examine the duration-effect relationship, we included all trials that compared two or
147 more different durations of the same antibiotic treatment for CAP.

148 149 *Types of participants*

150 Patients were eligible if they were 18 years or older of both genders with a diagnosis of
151 CAP as defined by the original authors. We included both outpatients and inpatients.
152 We excluded patients who were admitted to intensive care unit. In order to focus on
153 individuals at low to medium risk, we excluded trials with 20% or more patients
154 meeting one or more of the following criteria: having immunodeficiency; having been
155 treated with another antibiotic within a month.

156 157 *Types of interventions*

158 We included trials examining any antibiotics, administered orally or intravenously. We
159 evaluated antibiotics as a class because clinical guidelines recommend treatment
160 duration irrespective of the antibiotic used,⁴⁻⁶ and because recent meta-analyses of
161 antibiotics for CAP have not shown efficacy differences among antibiotics.^{22,23} Oral and
162 intravenous antibiotics were merged because they have been shown equally effective in
163 many infectious conditions within the same time frame.²⁴⁻²⁶ We included trials
164 comparing the same agents used at the same daily dosage but for different durations.
165 We used the predefined duration for fixed-duration arms. If some studies did not
166 prespecified the duration (eg. left it to clinicians' judgment¹¹), we used the median
167 duration.

168 169 **Primary outcome and secondary outcomes**

170 The primary outcome of interest in this study was clinical improvement as defined by
171 the original authors at a time point as close to 15 days (range 7-45 days) as possible in
172 each included study.²⁷ Secondary outcomes of interest were: all-cause mortality at day
173 15 (range 7-45 days), serious adverse events as defined by the original study at day 15
174 (range 7-45 days), and clinical improvement as defined by the original study at day 30

(range 15-60). We used the number of randomized patients as the denominator for intention-to-treat (ITT) dataset. When only clinical failure was reported, clinical improvement was calculated by subtracting clinical failure from the total number randomized. We used ITT for the primary analysis and per-protocol (PP) dataset for a sensitivity analysis.^{28,29} We used odds ratio (OR) of each outcome to synthesize data.^{30,31}

Search methods for identification of studies

Electronic searches

We systematically searched the following electronic bibliographic databases from inception to present (25 August, 2021): MEDLINE, Embase and CENTRAL. We used search terms for community acquired pneumonia in conjunction with the names of individual antibiotics as well as the names of antibiotic classes. Detailed search formulas are presented in the appendix (eAppendix2). We imposed no date, language or publication status restriction.

Reference lists

We checked the reference lists of all the included studies and review articles for additional references.

Data collection and analysis

Selection of studies

Two review authors independently screened and selected the included studies (YF and one of AO, EO, SF or YL). Two review authors extracted data independently from the included studies (YF and one of AO, EO, SF or YL). We used the Cochrane risk of bias tool Version 2³² to assess and summarize the risk of bias. Disagreements were resolved through discussion.

Statistical analysis

To perform our analyses, we used the *dosresmeta* package (Version 2.0.1) and *meta* package (Version 5.0-1) for R (Version 4.1.0. R foundation, Wien, Austria).³³⁻³⁵

Assessment of heterogeneity

We investigated the heterogeneity between studies by the variance partition coefficient (VPC).¹⁶ VPC represents the percentage of variation attributed to heterogeneity rather than sampling error and can be interpreted similarly to the I^2 .

Dose-effect meta-analysis

Given the clinical and methodological heterogeneity likely present in the included studies, we used the random effects model. We used 3 knots, equally spaced across the duration range (25%, 50%, 75%).^{17,18} We set 10 days as the reference because it can be regarded as the current practice.^{7,8,11} We tested the non-inferiority with the non-inferiority margin of 10%, as previously proposed,²⁷ and the superiority of the shorter duration examined against 10 days using ITT dataset.

Sensitivity analyses

In order to ascertain the robustness of the primary analyses, we conducted the following sensitivity analyses. To test the stability of the shape of the spline curves, we used different locations of knots (10%, 50%, 90%). To test the influence of trials included, we conducted sensitivity analyses excluding trials with an overall high risk of bias and excluding trials with outpatients. To test the robustness of the analytical method, we used the PP dataset. To test the influence of antibiotics examined, we conducted sensitivity analyses restricting eligible antibiotics only to those recommended by clinical guidelines for empirical treatment of CAP.^{4,5} In addition to the pre-defined sensitivity analyses, we conducted exploratory sensitivity analyses including only trials that randomized before the initial antibiotic treatment to test the influence of randomization timing.

Amendments

We report amendments with the date and the rationale in the appendix (eAppendix3).

RESULTS

We identified 1,994 records via database and one record via searching websites, which revealed that some different records refer to the same clinical trial. We assessed 38 full-text records for eligibility and included 11 eligible studies. (Fig1) Of these, 8 were published,^{11–15,36–38} 1 was unpublished³⁹ and 2 studies were still ongoing,^{40,41} resulting in 9 trials for the primary outcome analysis. The lists of included and excluded studies are provided in the appendix (eAppendix4 and 5). The 9 studies with 2,399 participants in total included 18 eligible arms. Treatment duration ranged from 3 to 10 days. The study year ranged between 1999 and 2021. Table 1 presents the characteristics of the included studies.

The included studies were all parallel-group and individually randomized. Seven out of nine were reported as non-inferiority trial. In total, 1,199 participants were randomly assigned to the shorter duration arm and 1,200 to the longer duration arm. The mean age

was 61.2 years (standard deviation 22.1); 831 (39%) of 2,140 reported were women. Six were conducted in a single European country, one in the US, and the two were cross-continental. CAP was defined as newly confirmed clinical symptoms (eg, dyspnoea, cough, purulent sputum, or crackles), and radiological findings. Clinical stability was often defined as apyrexia (temperature $\leq 37.8^{\circ}\text{C}$) for 48 hours, heart rate below 100 beats per min, respiratory rate below 24 breaths per min, arterial oxygen saturation of 90% or higher, systolic blood pressure of 90 mm Hg or higher, and normal mental status.⁴² Percentage of pneumonia severity index class IV or V was on average 19% (362 of 1,896 reported; ranging from 2 to 41%). Seven studies focused on inpatients, whereas one study focused on outpatients and one included both. Antibiotics used included β -lactam (amoxicillin, amoxicillin/clavulanate, ampicillin/sulbactam, ceftazidime, ceftriaxone, cefuroxime, piperacillin/tazobactam), macrolide (azithromycin, clarithromycin), quinolone (ciprofloxacin, gemifloxacin, levofloxacin, telithromycin), amikacin, doxycycline, and meropenem. Pharmaceutical companies funded four studies.^{13–15,36} Four studies had a high overall risk of bias, four some concerns, and only one had low overall risk of bias. (Table 1)

Assessment of heterogeneity

We assessed the heterogeneity in efficacy outcome across duration range (9 studies). VPC values were constantly below 10% which suggests low levels of heterogeneity. However, these assessments need to be carefully interpreted due to the small number of included studies. (eAppendix6)

Dose-effect meta-analysis

We present the duration-effect curves in Figure 2 and 3, and the tabulation of results in Table 2. The x-axis of the figures represents the treatment duration in days and the y-axis represents the odds ratio of the outcome. The thin solid horizontal line represents the odds ratio = 1 and the thin dotted horizontal line in the clinical improvement figures corresponds to the non-inferiority margin translated into OR. (The average percentage of clinical improvement rate at day 15 in the 10-day treatment arms was 68%. Non-inferiority margin was therefore 58% and the corresponding OR was 0.65. For clinical improvement at day 30, the numbers were 77%, 67% and OR 0.61, respectively.) The thick solid line represents the dose-effect curve and the thick dotted lines represent its 95% CI. The duration-effect curve is monotonic with longer duration leading to lower probability of improvement. The lower 95% CI curve was constantly above the prespecified non-inferiority margin, meaning that a shorter treatment duration

(3-9 days) was likely to be non-inferior to the standard treatment duration (10 days). It was slightly above the OR = 1 line around 3 days, suggesting 3-day treatment may be superior to 10-day treatment. Secondary outcomes had wider confidence interval curves. Harmful outcome curves (all-cause mortality and severe adverse events) were almost flat and 95%CI curves did not cross the OR = 1 line, indicating no association. Clinical improvement at day 30 showed a similar trend with the primary outcome with the lower 95%CI curve constantly above the prespecified non-inferiority margin. The average percentage of clinical improvement rate at day 15 in the 10-day treatment arms was 68% (based on a meta-analysis of the included studies). Using that average, we computed the absolute clinical improvement rates at the following durations: a 3-day treatment 75% (95%CI: 68 to 81%), 5-day treatment 72% (66 to 78%), and 7-day treatment 69% (61 to 76%).

Sensitivity analyses

Sensitivity analyses were in line with the primary analyses. (eAppendix7. Figures S1, using different locations of knots; S2.1, excluding trials with overall high risk of bias; S2.2, excluding trials with outpatients; S3, using PP dataset; S4 including only antibiotics recommended for empirical treatment of CAP by clinical guidelines). Exploratory sensitivity analyses showed that non-inferiority of the shorter duration was more likely to be the case in studies that randomized patients who had reached clinical stability early (eAppendix7. Figures S5.1, S5.2).

DISCUSSION

To our knowledge, this is the first systematic review and duration-effect meta-analysis of antibiotics treatment for CAP in adults. The results showed that a shorter treatment duration (3-9 days) was likely to be non-inferior to the standard treatment duration (10 days) for CAP in adults. There may be no significant difference in all-cause mortality or serious adverse events. A shorter range probably achieves the optimal balance between efficacy and treatment burden.

This is in line with the previous pair-wise meta-analysis that showed shorter duration was non-inferior to longer duration.¹⁰ Methodological limitations in a previous meta-analysis restricted authors from recommending a specific treatment duration. We overcame this limitation by examining the duration of antibiotic treatment range in days and found that a 3 to 9-day treatment is likely to be non-inferior to a 10-day treatment. Our results are in line with the guidelines for CAP recommending antibiotics to be prescribed for a duration shorter (5-8 days) than current clinical standard practice (10

319 days).⁴⁻⁶ Our results suggest that an even shorter duration (3-5 days) may be considered,
 320 which is in line with the trials that found 3-day treatment was non-inferior to 8-day
 321 treatment.^{12,37}

322

323 **Limitations**

324 Our study has several limitations. First, most of the included studies presented with
 325 moderate to high overall risk of bias. Second, the number of studies was small, leaving
 326 confidence intervals for secondary outcomes wide. Third, original studies excluded
 327 patients with complications of CAP and therefore the results of this study may not be
 328 generalizable to those patients. Forth, baseline severity of the included studies varied.
 329 However, the overall heterogeneity was low.

330

331 **Strengths**

332 First, we did a comprehensive systematic review and found 4 studies that were not
 333 included the previous systematic reviews. Second, we treated duration as a continuous
 334 variable, which allowed us to estimate the duration-effect relationship with greater
 335 resolution of change points. Third, we examined impacts of treatment duration not only
 336 for clinical improvement but also for all-cause mortality and severe adverse events and
 337 made sure that a shorter treatment duration would not translate into more harmful events.
 338 Finally, the very nature of shortened duration treatment offers a unique opportunity for
 339 interpretation. Shorter treatment durations have been examined by non-inferiority trials.
 340 The underlying assumption has been that there was a trade-off between a loss in
 341 efficacy of standard treatment duration and other benefits of a shortened duration,^{43,44}
 342 such as less time, less cost and probably a diminished rate of antimicrobial resistance.
 343 This study suggests that there may be even no trade-off for antibiotic treatments of 3 to
 344 5 days. Shorter treatment duration reduces the burden on patients, the healthcare system
 345 and the risk of antimicrobial resistance and might even offer better clinical outcomes at
 346 the same time.

347

348 **CONCLUSION**

349 Shorter treatment duration (3-9 days) was likely to be non-inferior to the standard
 350 treatment duration (10 days) for adults with CAP if they achieved clinical stability. A
 351 shorter range (3-5 days) probably results in an optimal balance between efficacy and
 352 treatment burden. However, the small number of included studies and the overall
 353 moderate to high risk of bias may compromise the certainty of the results. Further
 354 research focusing on the shorter duration range is required.

355

356

357 **Abbreviations**

358 CAP: community-acquired pneumonia

359 ITT: intention-to-treat

360 PP: per protocol

361 PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analyses

362 VPC: variance partition coefficient

363

364

365 **Registration**

366 This protocol was prospectively registered in PROSPERO (CRD 42021273357).

367

368 **Patient and public involvement**

369 Patients or the public were not involved in the design, conduct, reporting or

370 dissemination plans of this research.

371

372 **Ethics**

373 This study uses published aggregate data and did not require ethical approval.

374

375 **CRedit contribution statement**

376 **Yuki Furukawa:** Conceptualization, Methodology, Software, Validation, Formal
377 analysis, Data Curation, Writing – Original Draft, Visualization, Supervision, Project
378 administration

379 **Yan Luo:** Conceptualization, Methodology, Data Curation, Validation, Writing –
380 Review & Editing,

381 **Satoshi Funada:** Conceptualization, Methodology, Data Curation, Validation, Writing
382 – Review & Editing,

383 **Akira Onishi:** Conceptualization, Methodology, Data Curation, Validation, Writing –
384 Review & Editing,

385 **Edoardo G Ostinelli:** Conceptualization, Methodology, Data Curation, Validation,
386 Writing – Review & Editing,

387 **Tasnim Hamza:** Methodology, Software, Formal analysis, Visualization, Validation,
388 Writing – Review & Editing,

389 **Toshi A Furukawa:** Conceptualization, Methodology, Writing – Review & Editing,
390 Supervision,

391 **Yuki Kataoka:** Conceptualization, Methodology, Writing – Review & Editing,
392 Supervision,
393

394 **Funding**

395 None.
396

397 **Declarations of interest**

398 YL is receiving a Grant-in-Aid for JSPS Fellow (KAKENHI Grant Number 21J15050).

399 SF has a research grant from JSPS KAKENHI Grant Number JP 20K18964 and the
400 KDDI Foundation.

401 AO obtained speakers fees from Chugai Pharmaceutical Co. Ltd, Asahi Kasei
402 Corporation, Eli Lilly, AbbVie GK , Pfizer, Mistubishi Tanabe Pharma Corporation, and
403 GlaxoSmithKline plc, and research grants from Advantest and JSPS KAKENHI outside
404 the submitted work.

405 EGO has received research and consultancy fees from Angelini Pharma. EGO is
406 supported by the National Institute for Health Research (NIHR) Research Professorship
407 to Professor Andrea Cipriani (grant RP-2017-08-ST2-006), by the National Institute for
408 Health Research (NIHR) Applied Research Collaboration (ARC) Oxford and Thames
409 Valley, by the National Institute for Health Research (NIHR) Oxford cognitive health
410 Clinical Research Facility and by the NIHR Oxford Health Biomedical Research Centre
411 (grant BRC-1215-20005)

412 TAF reports grants and personal fees from Mitsubishi-Tanabe, personal fees from MSD,
413 personal fees from Shionogi, personal fees from Sony, outside the submitted work; In
414 addition, TAF has a patent 2018-177688 concerning smartphone CBT apps pending,
415 and intellectual properties for Kokoro-app licensed to Mitsubishi-Tanabe.

416 YK received a research grant from the Systematic Review Workshop Peer Support Group,
417 the Japan Osteoporosis Foundation, and Yasuda Memorial Medical Foundation for other
418 research purposes.

419 YF, TH declare no conflicts of interest.
420

421 **Data availability**

422 Data and code used for analyses are available from the corresponding author on
423 reasonable request.
424

425 REFERENCE

- 426 1. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global,
427 regional, and national morbidity, mortality, and aetiologies of lower respiratory
428 infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of
429 Disease Study 2016. *Lancet Infect Dis*. 2018;18(11):1191-1210.
430 doi:10.1016/s1473-3099(18)30310-4
- 431 2. Most Frequent Conditions in U.S. Hospitals, 2011. Accessed December 8, 2021.
432 <https://www.hcup-us.ahrq.gov/reports/statbriefs/sb162.pdf>
- 433 3. Xu J, Murphy SL, Kochanek KD, Bastian BA. Deaths: Final Data for 2013. *National*
434 *Vital Statistics Reports Centers Dis Control Prev National Cent Heal Statistics National*
435 *Vital Statistics Syst*. 2016;64(2):1-119.
- 436 4. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with
437 Community-acquired Pneumonia. An Official Clinical Practice Guideline of the
438 American Thoracic Society and Infectious Diseases Society of America. *Am J Resp Crit*
439 *Care*. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581st
- 440 5. National Institute of Health and Care Excellence (NICE). Pneumonia
441 (community-acquired): antimicrobial prescribing. Accessed December 8, 2021.
442 <https://www.nice.org.uk/guidance/NG138>
- 443 6. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower
444 respiratory tract infections - Full version. *Clin Microbiol Infec*. 2011;17(s6):E1-E59.
445 doi:10.1111/j.1469-0691.2011.03672.x
- 446 7. Aliberti S, Blasi F, Zanaboni AM, et al. Duration of antibiotic therapy in hospitalised
447 patients with community-acquired pneumonia. *Eur Respir J*. 2009;36(1):128-134.
448 doi:10.1183/09031936.00130909
- 449 8. Yi SH, Hatfield KM, Baggs J, et al. Duration of Antibiotic Use Among Adults With
450 Uncomplicated Community-Acquired Pneumonia Requiring Hospitalization in the
451 United States. *Clin Infect Dis*. 2017;66(9):1333-1341. doi:10.1093/cid/cix986

- 452 9. Guillemot D, Carbon C, Balkau B, et al. Low Dosage and Long Treatment Duration
453 of β -Lactam: Risk Factors for Carriage of Penicillin-Resistant *Streptococcus*
454 *pneumoniae*. *JAMA*. 1998;279(5):365-370. doi:10.1001/jama.279.5.365
- 455 10. Dimopoulos G, Matthaïou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa
456 Z, Falagas ME. Short- versus Long-Course Antibacterial Therapy for
457 Community-Acquired Pneumonia. *Drugs*. 2008;68(13):1841-1854.
458 doi:10.2165/00003495-200868130-00004
- 459 11. Uranga A, España PP, Bilbao A, et al. Duration of Antibiotic Treatment in
460 Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. *JAMA*
461 *Intern Med*. 2016;176(9):1257. doi:10.1001/jamainternmed.2016.3633
- 462 12. Dinh A, Ropers J, Duran C, et al. Discontinuing β -lactam treatment after 3 days for
463 patients with community-acquired pneumonia in non-critical care wards (PTC): a
464 double-blind, randomised, placebo-controlled, non-inferiority trial. *Lancet*.
465 2021;397(10280):1195-1203. doi:10.1016/s0140-6736(21)00313-5
- 466 13. Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 Versus 10 Days of
467 Antibiotic Therapy for Hospitalized Patients with Uncomplicated Community-Acquired
468 Pneumonia. *Am J Ther*. 1999;6(4):217-222. doi:10.1097/00045391-199907000-00007
- 469 14. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological
470 efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with
471 a 10 day regimen of clarithromycin twice daily in patients with mild to moderate
472 community-acquired pneumonia. *J Antimicrob Chemoth*. 2004;54(2):515-523.
473 doi:10.1093/jac/dkh356
- 474 15. File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily
475 for 5 days versus 7 days for the treatment of community-acquired pneumonia: a
476 randomized, multicentre, double-blind study. *J Antimicrob Chemoth*.
477 2007;60(1):112-120. doi:10.1093/jac/dkm119
- 478 16. Crippa A, Discacciati A, Bottai M, Spiegelman D, Orsini N. One-stage
479 dose-response meta-analysis for aggregated data. *Stat Methods Med Res*.
480 2019;28(5):1579-1596. doi:10.1177/0962280218773122

- 481 17. Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose
482 of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major
483 depression: a systematic review and dose-response meta-analysis. *Lancet Psychiatry*.
484 2019;6(7):601-609. doi:10.1016/s2215-0366(19)30217-2
- 485 18. Leucht S, Crippa A, Sifakis S, Patel MX, Orsini N, Davis JM. Dose-Response
486 Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. *Am J Psychiatr*.
487 2020;177(4):342-353. doi:10.1176/appi.ajp.2019.19010034
- 488 19. Højlund M, Kemp AF, Haddad PM, Neill JC, Correll CU. Standard versus reduced
489 dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a
490 systematic review and meta-analysis of randomised controlled trials. *Lancet Psychiatry*.
491 2021;8(6):471-486. doi:10.1016/s2215-0366(21)00078-x
- 492 20. Leucht S, Bauer S, Sifakis S, et al. Examination of Dosing of Antipsychotic Drugs
493 for Relapse Prevention in Patients With Stable Schizophrenia. *JAMA Psychiatr*.
494 2021;78(11). doi:10.1001/jamapsychiatry.2021.2130
- 495 21. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an
496 updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
497 doi:10.1136/bmj.n71
- 498 22. Montes-Andujar L, Tinoco E, Baez-Pravia O, et al. Empiric antibiotics for
499 community-acquired pneumonia in adult patients: a systematic review and a network
500 meta-analysis. *Thorax*. Published online 2021:thoraxjnl-2019-214054.
501 doi:10.1136/thoraxjnl-2019-214054
- 502 23. Pakhale S, Mulpuru S, Verheij TJ, Kochen MM, Rohde GG, Bjerre LM. Antibiotics
503 for community-acquired pneumonia in adult outpatients. *Cochrane Db Syst Rev*.
504 2014;10(10):CD002109. doi:10.1002/14651858.cd002109.pub4
- 505 24. Keren R, Shah SS, Srivastava R, et al. Comparative Effectiveness of Intravenous vs
506 Oral Antibiotics for Postdischarge Treatment of Acute Osteomyelitis in Children. *JAMA*
507 *Pediatr*. 2014;169(2):120. doi:10.1001/jamapediatrics.2014.2822
- 508 25. Li HK, Rombach I, Zambellas R, et al. Oral versus Intravenous Antibiotics for Bone
509 and Joint Infection. *New Engl J Med*. 2019;380(5):425-436.
510 doi:10.1056/nejmoa1710926

- 511 26. Iversen K, Ihlemann N, Gill SU, et al. Partial Oral versus Intravenous Antibiotic
512 Treatment of Endocarditis. *New Engl J Med*. 2019;380(5):415-424.
513 doi:10.1056/nejmoa1808312
- 514 27. Spellberg B, Talbot GH, Brass EP, et al. Position paper: recommended design
515 features of future clinical trials of antibacterial agents for community-acquired
516 pneumonia. *Clin Infect Dis Official Publ Infect Dis Soc Am*. 2008;47 Suppl 3:S249-65.
- 517 28. Bai AD, Komorowski AS, Lo CKL, et al. Intention-to-treat analysis may be more
518 conservative than per protocol analysis in antibiotic non-inferiority trials: a systematic
519 review. *BMC Med Res Methodol*. 2021;21(1):75. doi:10.1186/s12874-021-01260-7
- 520 29. Aberegg SK, Hersh AM, Samore MH. Empirical Consequences of Current
521 Recommendations for the Design and Interpretation of Noninferiority Trials. *J Gen*
522 *Intern Med*. 2018;33(1):88-96. doi:10.1007/s11606-017-4161-4
- 523 30. Bakbergenuly I, Hoaglin DC, Kulinskaya E. Pitfalls of using the risk ratio in
524 meta-analysis. *Res Synth Methods*. 2019;10(3):398-419. doi:10.1002/jrsm.1347
- 525 31. Doi SA, Furuya-Kanamori L, Xu C, Lin L, Chivese T, Thalib L. Questionable
526 utility of the relative risk in clinical research: A call for change to practice. *J Clin*
527 *Epidemiol*. Published online 2020. doi:10.1016/j.jclinepi.2020.08.019
- 528 32. Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias
529 in randomised trials. *BMJ*. 2019;366:l4898. doi:10.1136/bmj.l4898
- 530 33. Team RC. *R: A Language and Environment for Statistical Computing*. R
531 *Foundation for Statistical Computing*.; 2020. <https://www.R-project.org/>
- 532 34. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a
533 practical tutorial. *Évid Based Ment Heal*. 2019;22(4):153.
534 doi:10.1136/ebmental-2019-300117
- 535 35. Crippa A, Orsini N. Multivariate Dose-Response Meta-Analysis: The dosresmeta R
536 Package. Published online 2016. doi:doi.org/10.18637/jss.v072.c01
- 537 36. Léophonte P, Choutet P, Gaillat J, et al. Efficacité comparée de la ceftriaxone dans
538 un traitement de dix jours versus un traitement raccourci de cinq jours des pneumonies

539 aigues communautaires de l'adulte hospitalisé avec facteur de risque. *Médecine Et*
540 *Maladies Infect.* 2002;32(7):369-381. doi:10.1016/s0399-077x(02)00384-0

541 37. Rachida el Moussaoui, Corianne A J M de Borgie, Peterhans van den Broek, et al.
542 Effectiveness of discontinuing antibiotic treatment after three days versus eight days in
543 mild to moderate-severe community acquired pneumonia: randomised, double blind
544 study. *BMJ.* 2006;332(7554):1355. doi:10.1136/bmj.332.7554.1355

545 38. Aliberti S, Ramirez J, Giuliani F, et al. Individualizing duration of antibiotic therapy
546 in community-acquired pneumonia. *Pulm Pharmacol Ther.* 2017;45:191-201.
547 doi:10.1016/j.pupt.2017.06.008

548 39. Strålin K, Rubenson A, Lindroth H, et al. BETALACTAM TREATMENT UNTIL
549 NO FEVER FOR 48HOURS (AT LEAST 5 DAYS) VERSUS 10 DAYS IN
550 COMMUNITY-ACQUIRED PNEUMONIA: RANDOMISED, NON-INFERIORITY,
551 OPEN STUDY. In: Vol 3. Pneumonia. ; 2014:246-281. doi:10.1007/bf03399446

552 40. NCT03609099. Adequate Duration of Antibiotic Treatment in Community-acquired
553 Pneumonia With High Risk Class and Adequate Initial Clinical Response
554 (2017-001406-15). <https://clinicaltrials.gov/ct2/show/NCT03609099>

555 41. NCT04089787. Shortened Antibiotic Treatment of 5 Days in Community-Acquired
556 Pneumonia (CAP5). <https://clinicaltrials.gov/ct2/show/NCT04089787>

557 42. Halm EA, Fine MJ, Marrie TJ, et al. Time to Clinical Stability in Patients
558 Hospitalized With Community-Acquired Pneumonia: Implications for Practice
559 Guidelines. *JAMA.* 1998;279(18):1452-1457. doi:10.1001/jama.279.18.1452

560 43. Mulla SM, Scott IA, Jackevicius CA, You JJ, Guyatt GH. How to Use a
561 Noninferiority Trial: Users' Guides to the Medical Literature. *JAMA.*
562 2012;308(24):2605-2611. doi:10.1001/2012.jama.11235

563 44. Acuna SA, Chesney TR, Baxter NN. Incorporating Patient Preferences in
564 Noninferiority Trials. *JAMA.* 2019;322(4):305-306. doi:10.1001/jama.2019.7059

5 **Table 1 Characteristics of included studies**

Study	Age, mean, y		Female, %	PSI IV+V, %	Setting	Duration, day, median	Antibiotics	No. of participants	No. of clinical improvement at day 15	Risk of bias					Overall	Sponsored
	SD, y	Age, SD, y								D 1	D 2	D 3	D 4	D 5		
Siegel et al, 1999	61.1	15.1	NA	NA	Inpatient	7 10	CXM	25 27	21 20	L	H	H	L	S	H	Yes
Leophonte et al, 2002	64.0	18.7	25	NA	Inpatient	5 10	CRO	125 119	93 85	S	L	L	S	H	H	Yes
Tellier et al, 2004	45.8	18-87 †	42	7	Both	5 7	TEL	193 195	154 157	L	L	S	L	S	S	Yes
El Moussaoui et al, 2006	57.2*	23.9*	40	12	Inpatient	3 8	AMX	57 64	50 56	S	L	L	L	S	S	No
File et al, 2007	45.4	16.8	42	3	Outpatient	5 7	GMI	256 256	240 234	L	L	L	L	S	S	Yes
Stralin et al, 2014	NA	NA	NA	NA	Inpatient	5 10	β-lactam	103 103.5	79 81	H	H	H	H	H	H	No
Uranga et al, 2016	65.4	18.3	37	39	Inpatient	5 10	Various	162 150	90 71	S	L	L	S	S	S	No
Aliberti et al, 2017	60.6*	24.8*	40	24	Inpatient	6 8	Various	125 135	111 125	L	H	L	L	S	H	No
Dinh et al, 2021	73.2*	21.0*	41	39	Inpatient	3	β-lactum + placebo	152	117	L	L	L	L	L	L	No
						8	β-lactum + AMC	151	102							

* = calculated using median and interquartile range; † = range
 AMC = amoxicillin-clavulanic acid; AMX = amoxicillin; CRO = ceftriaxone; CXM = cefuroxime; D1 = Bias due to andomization; D2 = Bias due to deviations
 from inteded intervention; D3 = Bias due to missing data; D4 = Bias due to outcome measurement; D5 = Bias due toselection of reported result: GMI =
 gemifloxacin; H = high; L = low; PSI = pneumonia severity index; S = some cncerns; SD = standard deviation; TEL = telithromycin

Table 2 Tabulation of results

Outcome	Treatment duration (days)								(Reference)
		3		5		7		10	
Clinical improvement at day 15	OR	1.44	[1.01-2.05]	1.21	[0.90-1.63]	1.05	[0.74-1.50]	1.00	(reference)
	Rate	75%	[68-81%]	72%	[66-78%]	69%	[61-76%]	68%	(4 arms)
All-cause mortality	OR	1.11	[0.28-4.35]	0.93	[0.34-2.58]	0.84	[0.23-3.09]	1.00	(reference)
	Rate	3%	[1-11%]	3%	[1-7%]	2%	[1-8%]	3%	(3 arms)
Serious adverse events	OR	0.73	[0.27-1.96]	0.80	[0.51-1.24]	0.86	[0.40-1.85]	1.00	(reference)
	Rate	15%	[6-31%]	16%	[11-22%]	17%	[9-30%]	19%	(2 arms)
Clinical improvement at day 30	OR	1.24	[0.86-1.78]	1.16	[0.82-1.63]	1.09	[0.74-1.60]	1.00	(reference)
	Rate	81%	[74-86%]	80%	[74-85%]	79%	[73-84%]	77%	(4 arms)

'5

'6 **FIGURE LEGENDS**

'7

'8 **Figure 1 PRISMA flow diagram**

'9

'10 **Figure 2 Duration–effect relationship of antibiotics for CAP in adults. Clinical improvement at day** '11 **15.**

'12 OR=odds ratio. The dotted lines represent 95% confidence intervals. The thin horizontal dotted line
'13 represents the non-inferiority margin, corresponding with 10% absolute risk difference given the average
'14 event rate of 68%

'15

'16 **Figure 3 Duration–effect relationships of antibiotics for CAP in adults. (a) All-cause mortality. (b)** '17 **Severe adverse events. (c) Clinical improvement at day 30.**

'18 OR=odds ratio. The dotted lines represent 95% confidence intervals. The thin horizontal dotted line
'19 represents the non-inferiority margin, corresponding with 10% absolute risk difference given the average
'20 event rate of 77%

Figure 1 PRISMA flow diagram

Figure 2 Duration–effect relationship of antibiotics for CAP in adults. Clinical improvement at day 15.

OR=odds ratio. The dotted lines represent 95% confidence intervals. The thin horizontal dotted line represents the non-inferiority margin, corresponding with 10% absolute risk difference given the average event rate of 68%.

Figure 3 Duration–effect relationships of antibiotics for CAP in adults. (a) All-cause mortality. (b) Severe adverse events. (c) Clinical improvement at day 30.

OR=odds ratio. The dotted lines represent 95% confidence intervals. The thin horizontal dotted line represents the non-inferiority margin, corresponding with 10% absolute risk difference given the average event rate of 77%.